Isoliquiritigenin Attenuates Adipose Tissue Inflammation and Metabolic Syndrome by Modifying Gut Bacteria Composition in Mice
Isoliquiritigenin Attenuates Adipose Tissue Inflammation and Metabolic Syndrome by Modifying Gut Bacteria Composition in Mice
复制标题
DOI：
10.1002/mnfr.202101119
复制
发表时间：
2022-03-28
影响因子：
5.2
通讯作者：
Nagai, Yoshinori
中科院分区：
文献类型：
--
作者：
Ishibashi, Riko;Furusawa, Yukihiro;Nagai, Yoshinori
据报道，异甘草素 (ILG) 可减轻脂肪组织炎症和代谢紊乱；然而，其根本机制仍有待阐明。本研究的目的是阐明 ILG 是否通过肠道菌群修饰发挥抗炎和抗代谢综合征作用。方法和结果 给小鼠喂食高脂饮食 (HFD)，添加或不添加 ILG 长达 12 周。研究了 ILG 对体重、血糖水平、脂肪组织炎症、肠道屏障功能和肠道微生物群组成的影响。 ILG 补充剂可减轻 HFD 引起的肥胖、葡萄糖耐量和胰岛素抵抗，并抑制附睾白色脂肪组织 (eWAT) 中的炎症基因表达。此外，ILG 补充剂通过增加抗代谢疾病相关物种（例如金氏副杆菌和 Akkemansia muciniphila）的丰度以及上调与肠道屏障功能相关的基因来改变肠道细菌组成。来自 ILG 喂养供体的粪便微生物组移植 (FMT) 可以抵消 HFD 引起的身体和 eWAT 体重变化、炎症相关基因表达、葡萄糖耐量和胰岛素抵抗，从而表明 ILG 反应性肠道细菌发挥抗炎和抗代谢综合征作用。结论 肠道细菌的改变是 ILG 对脂肪组织炎症和代谢紊乱有益作用的基础。 ILG 可能是一种有前途的益生元，用于预防和治疗代谢综合征。
Scope Isoliquiritigenin (ILG) has been reported to attenuate adipose tissue inflammation and metabolic disorder; however, the underlying mechanisms remain to be elucidated. The aim of this study is to elucidate whether ILG shows the anti-inflammatory and antimetabolic syndrome effects through gut microbiota modification. Methods and results Mice are fed a high-fat diet (HFD) with or without ILG for up to 12 weeks. The effect of ILG on body weight, blood glucose level, adipose tissue inflammation, gut barrier function, and gut microbiota composition are investigated. ILG supplementation alleviates HFD-induced obesity, glucose tolerance, and insulin resistance and suppresses inflammatory gene expression in epididymal white adipose tissue (eWAT). Moreover, ILG supplementation modifies gut bacterial composition by increasing the abundance of antimetabolic disease-associated species (e.g., Parabacteroides goldsteinii and Akkemansia muciniphila) and up-regulated genes associated with gut barrier function. Fecal microbiome transplantation (FMT) from ILG-fed donors counteract HFD-induced body and eWAT weight changes, inflammation-related gene expression, glucose tolerance, and insulin resistance, thereby suggesting that ILG-responsive gut bacteria exerts anti-inflammatory and antimetabolic syndrome effects. Conclusion Alterations in gut bacteria underly the beneficial effects of ILG against adipose tissue inflammation and metabolic disorders. ILG may be a promising prebiotic for the prevention and treatment of metabolic syndrome.